SPC
BSX icon

Spirepoint Private Client’s Boston Scientific BSX Stock Holding History

Spirepoint Private Client’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Sell
6,675
-99,022
-94% -$5.38M 0.02% 273
2026
Q1 		$6.63M Buy
105,697
+11,613
+12% +$929K 0.63% 42
2025
Q4 		$8.97M Buy
94,084
+8,004
+9% +$785K 0.86% 33
2025
Q3 		$8.4M Buy
86,080
+4,053
+5% +$420K 0.88% 35
2025
Q2 		$8.81M Buy
82,027
+2,406
+3% +$243K 0.99% 29
2025
Q1 		$8.03M Buy
79,621
+6,596
+9% +$664K 1.05% 29
2024
Q4 		$6.52M Buy
73,025
+3,387
+5% +$298K 0.82% 36
2024
Q3 		$5.84M Buy
69,638
+1,343
+2% +$106K 0.77% 40
2024
Q2 		$5.26M Buy
68,295
+1,014
+2% +$74.2K 0.75% 33
2024
Q1 		$4.61M Buy
+67,281
New +$4.33M 0.7% 34

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Spirepoint Private Client's BSX Position: Q2 2026 in Review

Spirepoint Private Client reduced its Boston Scientific (BSX) stake by 94% in Q2 2026, selling an estimated $5.38M and leaving 6,675 shares worth $285K. The position accounts for 0.02% of the portfolio, ranked #273.

Spirepoint Private Client first reported a position in BSX in Q1 2024 and has held it in 10 quarters since. The position peaked at $8.97M in Q4 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Spirepoint Private Client held 6,675 shares of Boston Scientific worth $285K as of Q2 2026.
  • Spirepoint Private Client sold 99,022 Boston Scientific shares in Q2 2026, an estimated $5.38M.
  • Boston Scientific made up 0.02% of Spirepoint Private Client's portfolio in Q2 2026, its #273 holding.
  • Spirepoint Private Client first reported a position in Boston Scientific in Q1 2024 and has held it in 10 quarters since.
  • Spirepoint Private Client's Boston Scientific position peaked at $8.97M in Q4 2025.
  • 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Spirepoint Private Client's 13F filing for Q2 2026, filed 5 Aug 2026.